Trials and tribulations in systemic lupus erythematosus.
The pace of clinical trials activity in systemic lupus erythematosus (SLE) continues to accelerate. After decades of reliance on largely empiric approaches, a solid evidence-based foundation to guide our use of traditional agents, such as cyclophosphamide and azathioprine, is finally developing. In addition, we are learning how to integrate relatively new immunosuppressive agents, such as mycophenolate mofetil, into the treatment of SLE. These advances provide an important backdrop for recent trials designed to determine the potential value of several promising biologic therapies for SLE.
Division of Rheumatology, Department of Medicine, Rosalind Russell Medical Research Center, University of California, San Francisco, California 94121, USA. wofsyd@medsch.ucsf.edu
David
D
Wofsky
D002986:Clinical Trials as Topic; D019317:Evidence-Based Medicine; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D016896:Treatment Outcome
D007166:Immunosuppressive Agents